Clinical trial
An Open-Label, Single-Arm, Multicenter, Phase 2 Trial of Lenvatinib for the Treatment of Anaplastic Thyroid Cancer (ATC)
NCT02657369 is registered in ClinicalTrials.gov with Eisai Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- An Open-Label, Single-Arm, Multicenter, Phase 2 Trial of Lenvatinib for the Treatment of Anaplastic Thyroid Cancer (ATC)
- Lead sponsor
- Eisai Inc.
- Phase
- Phase 2
- Overall status
- Terminated
- Start date
- July 7, 2016
- Completion date
- September 26, 2018
- Enrollment
- 34 (actual)
- Sites
- 30
Conditions
As the registry lists them; a condition with its own page is linked.